John Mascarenhas, MD

Dr Mascarenhas on the Background of the MANIFEST-2 Trial in Myelofibrosis

May 11th 2023

John Mascarenhas, MD, discusses the background of the phase 3 MANIFEST-2 trial investigating the combination of pelabresib and ruxolitinib vs ruxolitinib plus placebo in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.

Dr. Mascarenhas on the Benefit of Fedratinib in Myelofibrosis

March 9th 2023

John Mascarenhas, MD, discusses the benefit of fedratinib for patients with myelofibrosis.

Dr. Mascarenhas on the Role of Pacritinib in Myelofibrosis

March 8th 2023

John Mascarenhas, MD, discusses the role of pacritinib in patients with myelofibrosis.

Myeloproliferative Neoplasm Management: Future Directions in Care

February 2nd 2023

Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.

Sequencing and Managing Combination Therapy in Myeloproliferative Neoplasms

January 26th 2023

Following their overview on novel treatment modalities in myeloproliferative neoplasms, expert panelists consider how best to sequence and manage novel therapies in practice.

An Expanding Armamentarium in MPNs: Therapeutic Strategies Under Investigation

January 26th 2023

A broad and comprehensive review of novel targeted agents under investigation in the setting of myeloproliferative neoplasm management.

Myeloproliferative Neoplasms: Targeting CALR With Novel Therapy

January 19th 2023

Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.

What is the Role of Transplant in Managing Patients With Myelofibrosis?

January 19th 2023

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Therapy in Myelofibrosis: Fedratinib and Ruxolitinib Strategies

January 12th 2023

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

Myelofibrosis: Nuancing the Potential of Disease Modification

January 12th 2023

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

Therapy in Myelofibrosis: Pacritinib

January 5th 2023

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

Novel Therapy in Myelofibrosis: Momelotinib

January 5th 2023

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Role of Symptom Burden in Thrombocythemia and Polycythemia Vera

December 22nd 2022

Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.

Overview on Essential Thrombocythemia and Polycythemia Vera Management

December 22nd 2022

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

Dr. Mascarenhas on Advancements in the Treatment Landscape of Myelofibrosis

November 28th 2022

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.

Dr. Mascarenhas on the Potential Clinical Significance of Pacritinib in Myelofibrosis

October 18th 2022

John O. Mascarenhas, MD, discusses the potential clinical significance of pacritinib in patients with myelofibrosis.

Dr. Mascarenhas on the Investigation of Pelabresib in Myelofibrosis

September 23rd 2022

John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.

Looking Deeper Inside Myelofibrosis

November 18th 2021

Dr. Mascarenhas on Potential for Pacritinib to Address an Unmet Need in Myelofibrosis

June 17th 2021

John O. Mascarenhas, MD, discusses the potential for pacritinib to address an unmet need in the treatment of patients with myelofibrosis.

Dr. Mascarenhas on the Promise of Imetelstat in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.